1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
Omar Venerio
Articles (1455) 

3 Stocks to Sell Friday

Redfin, Dropbox and Corcept Therapeutics stock smashed on earnings

August 10, 2018 | About:

Shares of Redfin Corp. (NASDAQ:RDFN) fell after the company reported second quarter earnings per share of 4 cents on revenue of $142.6 million, reflecting 35.9% year-over-year growth. The company beat earnings estimates by 2 cents and revenue estimates by $3.77 million.

Gross profit was $45.2 million, an increase of 22% from the second quarter of 2017. Gross margin was 32%, compared to 35%. Real estate services gross profit was $45.5 million, an increase of 22% and real estate services gross margin was 35%, compared to 37%.

Looking ahead, for the third quarter the company expects total revenue between $137.1 million and $141.3 million, reflecting 25% and 29% year-over-year growth, respectively. Properties segment revenue is expected to be between $10.1 million and $12.0 million.

Shares of Dropbox Inc. (NASDAQ:DBX) lost about 8% after reporting second quarter earnings per share of 11 cents on revenue of $339.million, reflecting 27.2% year-over-year growth. The company beat earnings estimates by cents and revenue estimates by $8.3 million.

Paying users totaled 11.9 million, higher than the 9.9 million for the same period of 2017. Average revenue per paying user was $116.66, also higher than the $111.19 figure for the same period last year.

GAAP gross margin was 73.6%, compared to 65.4% in the same period last year. Non-GAAP gross margin was 74.5%, compared to 66.7% in 2017GAAP operating margin was negative 2.1%, as compared to negative 10.0%. Non-GAAP operating margin was 14.1%, higher than 8.0%.

Corcept Therapeutics Inc. (NASDAQ:CORT) also fell on Friday mornings ahead of second quarter earnings per share of 20 cents on revenue of $62.31 million. Both figures fell short of estimates by 4 cents and by $6.19 million, respectively.

“Our Cushing’s syndrome franchise continues its significant growth, driven by physicians’ increasing realization that hypercortisolism is a serious disorder and that cortisol modulation is the best medical therapy for many patients,” said Joseph K. Belanoff, MD, Corcept’s CEO.

Disclosure: The author holds no position in any stocks mentioned.

About the author:

Omar Venerio
Omar Venerio is a capital markets, derivatives, corporate finance and financial management professor. He is passionate about the stock market and providing independent fundamental research and hedge fund and insider trading-focused investigation.

Rating: 0.0/5 (0 votes)


Please leave your comment:

Performances of the stocks mentioned by Omar Venerio

User Generated Screeners

pascal.van.garsseHigh FCF-M2
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat